Joseph has made over 5 trades of the Biospecifics Technologies stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 133,484 units of BSTC stock worth $419,140 on 16 October 2019.
The largest trade he's ever made was exercising 133,484 units of Biospecifics Technologies stock on 16 October 2019 worth over $419,140. On average, Joseph trades about 11,285 units every 93 days since 2009. As of 16 October 2019 he still owns at least 136,984 units of Biospecifics Technologies stock.
You can see the complete history of Mr. Truitt stock trades at the bottom of the page.
Joseph Truitt serves as Chief Executive Officer, Director of the Company. He previously served as the President and Chief Executive Officer of Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) (“Achillion”), a clinical-stage biopharmaceutical company that discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Prior to his appointment as President and Chief Executive Officer in 2018, Mr. Truitt served in a number of various positions at Achillion, including Executive Vice President, Chief Operations Officer (2017 to 2018) and Executive Vice President, Chief Commercial Officer (2009 to 2017). Before joining Achillion, from 2006 to 2008, Mr. Truitt was the Vice President, Business Development and Product Strategy of Lev Pharmaceuticals, Inc. and, from 2000 to 2006, he served as Vice President, Sales and Operations of Johnson & Johnson – OraPharma, Inc. Prior to this, he spent nine years at TAP Pharmaceuticals Inc. in a variety of sales and marketing roles before a two-year role as a consultant at IMS Health. Mr. Truitt received his B.S. in Marketing from LaSalle University and his M.B.A. from St. Joseph’s University. Mr. Truitt previously was a Captain in the United States Marine Corps.
Joseph Truitt is 55, he's been the Chief Executive Officer és Director of Biospecifics Technologies since 2020. There are 5 older and 2 younger executives at Biospecifics Technologies. The oldest executive at Biospecifics Technologies Corp. is Toby Wegman, 85, who is the Director.
Joseph's mailing address filed with the SEC is C/O BIOSPECIFICS TECHNOLOGIES CORP., 2 RIGHTER PKWY, DE CORP CENTER II, WILMINGTON, DE, 19803.
Over the last 33 years, insiders at Biospecifics Technologies have traded over $67,860,045 worth of Biospecifics Technologies stock and bought 7,761,661 units worth $656,708,120 . The most active insiders traders include Capital Management, Llc Kol..., International Plc Endo és Max Link. On average, Biospecifics Technologies executives and independent directors trade stock every 73 days with the average trade being worth of $6,538,649. The most recent stock trade was executed by International Plc Endo on 2 December 2020, trading 7,344,955 units of BSTC stock currently worth $650,028,518.
Biospecifics Technologies executives and other stock owners filed with the SEC include: